Endothelial dysfunction in chronic kidney disease: Determinant of susceptibility to end-organ damage and therapeutic response

Journal of Nephrology

Volumn 19, Issue 3, 2006, Pages 246-258

  Ochodnicky, Peter ^a   Vettoretti, S ^a   Henning, R H ^a   Buikema, H ^a   Van Dokkum, P E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; FOLIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; N(G) NITROARGININE METHYL ESTER; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; VASOPEPTIDASE INHIBITOR;

AGING; ALBUMINURIA; AREA UNDER THE CURVE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; GLOMERULOSCLEROSIS; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY INJURY; MICROALBUMINURIA; NONHUMAN; PRIMARY PREVENTION; PROTEINURIA; RENAL PROTECTION; REVIEW; TREATMENT RESPONSE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

CARDIOVASCULAR DISEASES; DISEASE SUSCEPTIBILITY; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 33749073195     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-47.
2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69.
3. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004; 15: 1983-92.
4. Goligorsky MS. Endothelial cell dysfunction: can't live with it, how to live without it. Am J Physiol Renal Physiol 2005; 288: F871-80.
5. Stehouwer CD. Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant 2004; 19: 778-81.
6. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Luscher TF, Mancia G, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Spieker LE, Taddei S, Webb DJ. Endothelial function and dysfunction, Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 233-46.
7. Morris ST, Jardine AG. The vascular endothelium in chronic renal failure. J Nephrol 2000; 13: 96-105.
8. Gris JC, Branger B, Vecina F, al Sabadani B, Fourcade J, Schved JF. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994; 46: 807-13.
9. Nakayama M, Yamada K, Yamamoto Y, Yokoyama K, Nakano H, Kubo H, Shigematsu T, Kawaguchi Y, Sakai O. Vascular endothelial dysfunction in patients on regular dialysis treatment. Clin Nephrol 1994; 42: 117-20.
10. Cupisti A, Rossi M, Placidi S, Caprioli R, Morelli E, Vagheggini G, Barsotti G. Responses of the skin microcirculation to acetylcholine and to sodium nitroprusside in chronic uremic patients. Int J Clin Lab Res 2000; 30: 157-62.
11. Passauer J, Bussemaker E, Range U, Plug M, Gross P. Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilation in normotensive patients on chronic hemodialysis. J Am Soc Nephrol 2000; 11: 1726-34.
12. Morris ST, McMurray JJ, Spiers A, Jardine AG. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 2001; 60: 1077-82.
13. Annuk M, Lind L, Linde T, Fellstrom B. Impaired endothelium-dependent vasodilatation in renal failure in humans. Nephrol Dial Transplant 2001; 16: 302-6.
14. Kari JA, Donald AE, Vallance DT, Bruckdorfer KR, Leone A, Mullen MJ, Bunce T, Dorado B, Deanfield JE, Rees L. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int 1997; 52: 468-72.
15. Koobi P, Kalliovalkama J, Jolma P, Rysa J, Ruskoaho H, Vuolteenaho O, Kahonen M, Tikkanen I, Fan M, Ylitalo P, Porsti I. AT1 receptor blockade improves vasorelaxation in experimental renal failure. Hypertension 2003; 41: 1364-71.
16. Koobi P, Jolma P, Kalliovalkama J, Tikkanen I, Fan M, Kahonen M, Moilanen E, Porsti I. Effect of angiotensin II type 1 receptor blockade on conduit artery tone in subtotally nephrectomized rats. Nephron Physiol 2004; 96: 91-8.
17. Passauer J, Pistrosch F, Bussemaker E, Lassig G, Herbrig K, Gross P. Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide. J Am Soc Nephrol 2005; 16: 959-65.
18. Ferraro B, Galli F, Frei B, Kingdon E, Canestrari F, Rice-Evans C, Buoncristiani U, Davenport A, Moore KP. Peroxynitrite-induced oxidation of plasma lipids is enhanced in stable hemodialysis patients. Kidney Int 2003; 63: 2207-13.
19. Hasdan G, Benchetrit S, Rashid G, Green J, Bernheim J, Rathaus M. Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. Kidney Int 2002; 61: 586-90.
20. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 2001; 12: 2747-52.
21. Cross JM, Donald AE, Nuttall SL, Deanfield JE, Woolfson RG, Macallister RJ. Vitamin C improves resistance but not conduit artery endothelial function in patients with chronic renal failure. Kidney Int 2003; 63: 1433-42.
22. Ghiadoni L, Cupisti A, Huang Y, Mattei P, Cardinal H, Favilla S, Rindi P, Barsotti G, Taddei S, Salvetti A. Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol 2004; 17: 512-9.
23. Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999; 10: 891-900.
24. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 2000; 279: F671-8.
25. Virdis A, Ghiadoni L, Cardinal H, Favilla S, Duranti P, Birindelli R, Magagna A, Bernini G, Salvetti G, Taddei S, Salvetti A. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension. J Am Coll Cardiol 2001; 38: 1106-15.
26. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
27. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000; 58: 1261-6.
28. Annuk M, Fellstrom B, Lind L. Cyclooxygenase inhibition improves endothelium-dependent vasodilatation in patients with chronic renal failure. Nephrol Dial Transplant 2002; 17: 2159-63.
29. Ochodnicky P, Vettoretti S, Henning RH, Kluppel CA, de Zeeuw D, van Dokkum RP. Concomitant decrease of systemic arterial myogenic tone and EDHF-mediated dilation in subtotally nephrectomized rat (abstract). J Am Soc Nephrol 2005; 16: 185A.
30. Feletou M, Vanhoutte PM. EDHF: new therapeutic targets? Pharmacol Res 2004; 49: 565-80.
31. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci 2002; 23: 374-80.
32. Kohler R, Eichler I, Schonfelder H, Grgic I, Heinau P, Si H, Hoyer J. Impaired EDHF-mediated vasodilation and function of endothelial Ca-activated K channels in uremic rats. Kidney Int 2005; 67: 2280-7.
33. Pannier B, Guerin AP, Marchais SJ, Metivier F, Safar ME, London GM. Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease. Kidney Int 2000; 57: 1091-9.
34. Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61: 609-14.
35. Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005; 67: 2330-7.
36. Segarra A, Chacon P, Martinez-Eyarre C, Argelaguer X, Vila J, Ruiz P, Fort J, Bartolome J, Camps J, Moliner E, Pelegri A, Marco F, Olmos A, Piera L. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol 2001; 12: 1255-63.
37. Zoccali C. Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease. Blood Purif 2002; 20: 469-72.
38. London GM, Pannier B, Agharazii M, Guerin AP, Verbeke FH, Marchais SJ. Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int 2004; 65: 700-4.
39. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Abnormalities of endothelial function in patients with predialysis renal failure. Heart 2000; 83: 205-9.
40. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 219-26.
41. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-60.
42. Yudkin JS. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988; 2: 530-3.
43. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-82.
44. Clausen P, Jacobsen P, Rossing K, Jensen JS, Parving HH, Feldt-Rasmussen B. Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with Type 1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabet Med 2000; 17: 644-9.
45. Perticone F, Maio R, Tripepi G, Zoccali C. Endothelial dysfunction and mild renal insufficiency in essential hypertension. Circulation 2004; 110: 821-5.
46. Dogra G, Rich L, Stanton K, Watts GF. Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria. Diabetologia 2001; 44: 593-601.
47. Papaioannou GI, Seip RL, Grey NJ, Katten D, Taylor A, Inzucchi SE, Young LH, Chyun DA, Davey JA, Wackers FJ, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Engel S, Heller GV. Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study). Am J Cardiol 2004; 94: 294-9.
48. Feldt-Rasmussen B. Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1986; 29: 282-6.
49. Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci (Lond) 1995; 88: 629-33.
50. Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 2001; 103: 1869-74.
51. Paisley KE, Beaman M, Tooke JE, Mohamed-Ali V, Lowe GD, Shore AC. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int 2003 63: 624-33.
52. Clausen P, Feldt-Rasmussen B, Jensen G, Jensen JS. Endothelial haemostatic factors are associated with progression of urinary albumin excretion in clinically healthy subjects: a 4-year prospective study. Clin Sci (Lond) 1999; 97: 37-43.
53. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-23.
54. Elliott TG, Cockcroft JR, Groop PH, Viberti GC, Ritter JM. Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin Sci (Lond) 1993; 85: 687-93.
55. Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter LM. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction - the Hoorn Study. Kidney Int Suppl 2004; 92: S42-4.
56. Giner V, Tormos C, Chaves FJ, Saez G, Redon J. Microalbuminuria and oxidative stress in essential hypertension. J Intern Med 2004; 255: 588-94.
57. Ozdemir G, Ozden M, Maral H, Kuskay S, Cetinalp P, Tarkun I. Malondialdehyde, glutathione, glutathione peroxidase and homocysteine levels in type 2 diabetic patients with and without microalbuminuria. Ann Clin Biochem 2005; 42: 99-104.
58. de Luis DA, Fernandez N, Arranz ML, Aller R, Izaola O, Romero E. Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2. J Diabetes Complications 2005; 19: 42-6.
59. Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jakobs C, Bouter LM, Donker AJ, Stehouwer CD. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int 1998; 54: 203-9.
60. Gschwend S, Pinto-Sietsma SJ, Buikema H, Pinto YM, van Gilst WH, Schulz A, de Zeeuw D, Kreutz R. Impaired coronary endothelial function in a rat model of spontaneous albuminuria. Kidney Int 2002; 62: 181-91.
61. Ochodnicky P, Henning RH, Provoost AP, de Zeeuw D, van Dokkum RP. Heterogeneity of systemic and renal endothelial dysfunction in a rat model of hypertension-associated renal damage [abstract]. J Am Soc Nephrol 2005; 16: 185A.
62. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. Diabetes 2000; 49: 485-91.
63. Stehouwer CD, Gall MA, Hougaard P, Jakobs C, Parving HH. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int 1999; 55: 308-14.
64. Verhave JC, Gansevoort RT, Hillege HL, Bakker SJ, de Zeeuw D, de Jong PE. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl 2004; 92: S18-21.
65. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; 1: 1430-2.
66. Dalla Vestra M, Sacerdoti D, Bombonato G, Fioretto P, Finucci G, Saller A, Sfriso A, Bruseghin M, Sambataro M, Velussi M, Baggio B, Nosadini R, Crepaldi G. Nitric oxide modulation of renal and cardiac hemodynamics in type 2 diabetes. Eur J Endocrinol 2002; 146: 687-94.
67. Higashi Y, Oshima T, Ozono R, Matsuura H, Kajiyama G. Aging and severity of hypertension attenuate endothelium-dependent renal vascular relaxation in humans. Hypertension 1997; 30: 252-8.
68. van den Meiracker AH, van der Linde NA, Broere A, Derkx FH, Boomsma F. Effects of L-arginine and L-NAME on the renal function in hypertensive and normotensive subjects. Nephron 2002; 91: 444-51.
69. Hayashi K, Matsuda H, Nagahama T, Fujiwara K, Ozawa Y, Kubota E, Honda M, Tokuyama H, Saruta T. Impaired nitric oxide-independent dilation of renal afferent arterioles in spontaneously hypertensive rats. Hypertens Res 1999; 22: 31-7.
70. Hayashi K, Kanda T, Homma K, Tokuyama H, Okubo K, Takamatsu I, Tatematsu S, Kumagai H, Saruta T. Altered renal microvascular response in Zucker obese rats. Metabolism 2002; 51: 1553-61.
71. Long DA, Newaz MA, Prabhakar SS, Price KL, Truong LD, Feng L, Mu W, Oyekan AO, Johnson RJ. Loss of nitric oxide and endothelial-derived hyperpolarizing factor-mediated responses in aging. Kidney Int 2005; 68: 2154-63.
72. Baylis C, Qiu C. Importance of nitric oxide in the control of renal hemodynamics. Kidney Int 1996; 49: 1727-31.
73. Zatz R, Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension 1998; 32: 958-64.
74. Fujihara CK, Michellazzo SM, de Nucci G, Zatz R. Sodium excess aggravates hypertension and renal parenchymal injury in rats with chronic NO inhibition. Am J Physiol 1994; 266: F697-705.
75. Kashiwagi M, Shinozaki M, Hirakata H, Tamaki K, Hirano T, Tokumoto M, Goto H, Okuda S, Fujishima M. Locally activated renin-angiotensin system associated with TGF-beta1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 2000; 11: 616-24.
76. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992; 90: 278-81.
77. Reyes AA, Purkerson ML, Karl I, Klahr S. Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis 1992; 20: 168-76.
78. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002; 13: 806-16.
79. Kang DH, Nakagawa T, Feng L, Johnson RJ. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 2002; 161: 239-48.
80. Feldman HI, Klag MJ, Chiapella AP, Whelton PK. End-stage renal disease in US minority groups. Am J Kidney Dis 1992; 19: 397-410.
81. Hayden PS, Iyengar SK, Schelling JR, Sedor JR. Kidney disease, genotype and the pathogenesis of vasculopathy. Curr Opin Nephrol Hypertens 2003 12: 71-8.
82. Provoost AP. Spontaneous glomerulosclerosis: insights from the fawn-hooded rat. Kidney Int Suppl 1994; 45: S2-5.
83. Bowden DW. Genetics of kidney disease. Kidney Int Suppl 2003; 83: S8-12.
84. Korstanje R, DiPetrillo K. Unraveling the genetics of chronic kidney disease using animal models. Am J Physiol Renal Physiol 2004; 287: F347-52.
85. Fitzgibbon WR, Greene EL, Grewal JS, Hutchison FN, Self SE, Latten SY, Ullian ME. Resistance to remnant nephropathy in the Wistar-Furth rat. J Am Soc Nephrol 1999; 10: 814-21.
86. Erdely A, Freshour G, Smith C, Engels K, Olson JL, Baylis C. Protection against puromycin aminonucleosideinduced chronic renal disease in the Wistar-Furth rat. Am J Physiol Renal Physiol 2004; 287: F81-9.
87. Erdely A, Wagner L, Muller V, Szabo A, Baylis C. Protection of wistar furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase. J Am Soc Nephrol 2003; 14: 2526-33.
88. Muller V, Engels K, Baylis C. Chronic inhibition of nitric oxide synthase (NOS) renders the C57BL6 mouse susceptible to the development of chronic renal disease [abstract]. J Am Soc Nephrol 2003; 14: 625A.
89. Gschwend S, Buikema H, Navis G, Henning RH, de Zeeuw D, van Dokkum RP. Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat. J Am Soc Nephrol 2002; 13: 2909-15.
90. Ochodnicky P, Henning RH, Buikema H, de Zeeuw D, van Dokkum RP. Renal endothelial function predicts the individual susceptibility to Adriamycin-induced renal damage [abstract]. J Am Soc Nephrol 2005; 16: 800A.
91. Ochodnicky P, de Zeeuw D, Henning RH, Kluppel CA, van Dokkum RP. Endothelial function predicts the development of renal damage after combined nephrectomy and myocardial infarction. J Am Soc Nephrol 2006; 17 (Suppl 2): S49-52.
92. Nagase S, Suzuki H, Wang Y, Kikuchi S, Hirayama A, Ueda A, Takada K, Oteki T, Obara M, Aoyagi K, Koyama A. Association of ecNOS gene polymorphisms with end stage renal diseases. Mol Cell Biochem 2003; 244: 113-8.
93. Noiri E, Satoh H, Taguchi J, Brodsky SV, Nakao A, Ogawa Y, Nishijima S, Yokomizo T, Tokunaga K, Fujita T. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 2002; 40: 535-40.
94. Passauer J, Bussemaker E, Lassig G, Gross P. Kidney transplantation improves endothelium-dependent vasodilation in patients with endstage renal disease. Transplantation 2003; 75: 1907-10.
95. Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM, Frolich JC. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10: 594-600.
96. McGregor DO, Buttimore AL, Lynn KL, Yandle T, Nicholls MG. Effects of long and short hemodialysis on endothelial function: a short-term study. Kidney Int 2003; 63: 709-15.
97. Miyazaki H, Matsuoka H, Itabe H, Usui M, Ueda S, Okuda S, Imaizumi T. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation 2000; 101: 1002-6.
98. Bennett-Richards KJ, Kattenhorn M, Donald AE, Oakley GR, Varghese Z, Bruckdorfer KR, Deanfield JE, Rees L. Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int 2002; 62: 1372-8.
99. Chan NN, Chan WB, Chan JC. Reduction of total homocysteine levels by oral folic acid fails to improve endothelial function in children with chronic renal failure. Circulation 2003; 107: e6-7.
100. Cross JM, Donald AE, Kharbanda R, Deanfield JE, Woolfson RG, Macallister RJ. Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure. Kidney Int 2001; 60: 2318-23.
101. Tepel M, van der GM, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107: 992-5.
102. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-18.
103. Arcaro G, Zenere BM, Saggiani F, Zenti MG, Monauni T, Lechi A, Muggeo M, Bonadonna RC. ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria. Diabetes Care 1999; 22: 1536-42.
104. Gasic S, Wagner OF, Fasching P, Ludwig C, Veitl M, Kapiotis S, Jilma B. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens 1999; 12: 217-22.
105. Schalkwijk CG, Smulders RA, Lambert J, Donker AJ, Stehouwer CD. ACE-inhibition modulates some endothelial functions in healthy subjects and in normotensive type 1 diabetic patients. Eur J Clin Invest 2000; 30: 853-60.
106. Tan KC, Chow WS, Ai VH, Lam KS. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Diabetes Metab Res Rev 2002; 18: 71-6.
107. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202.
108. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809-16.
109. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
110. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60: 1131-40.
111. Laverman GD, de Zeeuw D, Navis G. Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy? J Renin Angiotensin Aldosterone Syst 2002; 3: 205-13.
112. van Dokkum RP, Vettoretti S, Ochodnicky P, Kluppel CA, Henning RH, de Zeeuw D. Endothelial function of small renal arteries of healthy rat predicts the antiproteinuric response to ACE-inhibitor (ACE-i) therapy following 5/6 nephrectomy (Nx) [abstract]. J Am Soc Nephrol 2005; 16: 164A.
113. Patzak A, Lai E, Persson PB, Persson AE. Angiotensin II-nitric oxide interaction in glomerular arterioles. Clin Exp Pharmacol Physiol 2005; 32: 410-4.